AstraZeneca, the second biggest foreign pharmaceutical company in China after Pfizer, has strengthened its position in this market by acquiring Guangdong BeiKang Pharmaceutical, a manufacturer of generic injectable antibiotics, for an undisclosed sum. With the acquisition, AstraZeneca will gain a portfolio of five injectable medicines used in the treatment of infections.